ARWR · Arrowhead Pharmaceuticals, Inc.
$58.02
-0.58% last session
End-of-day data · close of 2026-10-23
Market cap
$8B
Enterprise value
$8B
Trailing P/E
—
Forward P/E
-11.7
Dividend yield
0.0%
Beta
1.30
Avg volume
2M
Employees
1K
Daily Change %
-0.58%
5 Days Change
4.40%
10 Days Change
0.40%
30 Days Change
-12.84%
60 Days Change
-32.71%
Month to Day Change
-9.92%
Year to Day Change
-12.10%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ARWR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
Citigroup
Buy$108
+86.1% vs priceRBC Capital
Outperform$100
+72.4% vs priceMorgan Stanley
Overweight$120
+106.8% vs priceJP Morgan
Overweight$95.00
+63.7% vs priceGoldman Sachs
Neutral$85.00
+46.5% vs priceBank of America
Buy$81.00
+39.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Chardan Capital | Maintains | Buy | $115 |
| 2026-10-15 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-09-08 | Citigroup | Initiates | Buy | $0.00 → $108 |
| 2026-09-01 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-08-31 | Chardan Capital | Maintains | Buy | $115 |
| 2026-08-31 | RBC Capital | Reiterates | Outperform | $100 |
| 2026-08-06 | HC Wainwright & Co. | Maintains | Buy | $115 → $120 |
| 2026-07-30 | B. Riley Securities | Maintains | Buy | $101 → $123 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 20.1% below the 50-day MA ($72.62).
- bearish: Price vs 200-day MA: Trading 19.3% below the 200-day MA ($71.87).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.51) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($37.35) and high ($89.59).
ARWR Price Chart
Loading chart for ARWR…
Fundamentals
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.